Gliprip-M1 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. The extended-release formulation of Gliprip-M1 Forte Tablet PR allows for sustained drug release, promoting better glycemic control with reduced dosing frequency and improved patient compliance. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea, vomiting, and diarrhea, and rarely, lactic acidosis. Gliprip-M1 Forte Tablet PR should be used under medical supervision, with lifestyle modifications including diet and exercise to maximize therapeutic outcomes.